Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence

Neuroscience Letters

Volumn 434, Issue 1, 2008, Pages 88-92

  Otani, Kyohei ^a   Ujike, Hiroshi ^a,b   Sakai, Ayumu ^a   Okahisa, Yuko ^a   Kotaka, Tatsuya ^a   Inada, Toshiya ^b,c   Harano, Mutsuo ^b,d   Komiyama, Tokutaro ^b,e   Hori, Toru ^b,f   Yamada, Mitsuhiko ^b,g   Sekine, Yoshimoto ^b,h   Iwata, Nakao ^b,i   Iyo, Masaomi ^b,j   Sora, Ichiro ^b,k   Ozaki, Norio ^b,l   Kuroda, Shigetoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Japanese Genetics Initiative for Drug Abuse ^*  (Japan)

^c SEIWA HOSPITAL   (Japan)

^d Kurume University Graduate School of Medicine Kurume University Graduate School of Medicine Graduate School Biostatistics   (Japan)

^e Iida Hospital   (Japan)

^f Toyama Medical and Pharmaceutical University   (Japan)

^g NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^h HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Amphetamine; Case control association study; CYP2D6; Dependence; Intermediate metabolizer; Methamphetamine

Indexed keywords

CYTOCHROME P450 2D6; METHAMPHETAMINE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYDROXYLATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AMPHETAMINE-RELATED DISORDERS; BRAIN; BRAIN DISEASES, METABOLIC; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CYTOCHROME P-450 CYP2D6; DNA MUTATIONAL ANALYSIS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; JAPAN; MALE; METABOLIC DETOXICATION, DRUG; METHAMPHETAMINE; MIDDLE AGED; RISK FACTORS;

EID: 40649086616     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.01.033     Document Type: Article

References (43)

1. Anggard E., Jonsson L.E., Hogmark A.L., and Gunne L.M. Amphetamine metabolism in amphetamine psychosis. Clin. Pharmacol. Ther. 14 (1973) 870-880
2. Arinami T., Ishiguro H., and Onaivi E.S. Polymorphisms in genes involved in neurotransmission in relation to smoking. Eur. J. Pharmacol. 410 (2000) 215-226
3. Bertilsson L., Dahl M.L., Dalen P., and Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53 (2002) 111-122
4. Billings R.E., Murphy P.J., McMahon R.E., and Ashmore J. Aromatic hydroxylation of amphetamine with rat liver microsomes, perfused liver, and isolated hepatocytes. Biochem. Pharmacol. 27 (1978) 2525-2529
5. Bosron W.F., and Li T.K. Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism. Hepatology 6 (1986) 502-510
6. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3 (2002) 229-243
7. Broly F., Gaedigk A., Heim M., Eichelbaum M., Morike K., and Meyer U.A. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 10 (1991) 545-558
8. Caldwell J., Dring L.G., and Williams R.T. Metabolism of (14C)methamphetamine in man, the guinea pig and the rat. Biochem. J. 129 (1972) 11-22
9. Cho A.K., Hodshon B.J., Lindeke B., and Jonsson J. The p-hydroxylation of amphetamine and phentermine by rat liver microsomes. Xenobiotica 5 (1975) 531-538
10. Dougan D.F., Duffield A.M., Duffield P.H., and Wade D.N. Stereoselective accumulation of hydroxylated metabolites of amphetamine in rat striatum and hypothalamus. Br. J. Pharmacol. 88 (1986) 285-290
11. Dougan D.F., Labrie S.L., Paull P.D., Duffield P.H., and Wade D.N. Evidence that alpha-methyl-p-tyramine is implicated in behavioural augmentation to amphetamine. Gen. Pharmacol. 17 (1986) 453-456
12. Dougan D.F., Wade D.N., and Duffield P. How metabolites may augment some psychostimulant actions of amphetamine. TiPS 8 (1987) 277-280
13. Fischer J.F., and Cho A.K. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208 (1979) 203-209
14. Gasche Y., Daali Y., Fathi M., Chiappe A., Cottini S., Dayer P., and Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351 (2004) 2827-2831
15. Heim M., and Meyer U.A. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336 (1990) 529-532
16. Higuchi S., Matsushita S., Murayama M., Takagi S., and Hayashida M. Alcohol and aldehyde dehydrogenase polymorphisms and the risk for alcoholism. Am. J. Psychiatry 152 (1995) 1219-1221
17. Hiroi N., and Agatsuma S. Genetic susceptibility to substance dependence. Mol. Psychiatry 10 (2005) 336-344
18. Ide S., Kobayashi H., Ujike H., Ozaki N., Sekine Y., Inada T., Harano M., Komiyama T., Yamada M., Iyo M., Iwata N., Tanaka K., Shen H., Iwahashi K., Itokawa M., Minami M., Satoh M., Ikeda K., and Sora I. Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms. Pharmacogenomics J. 6 (2006) 179-188
19. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshiya Y., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Inada T., and Ozaki N. Positive association of AKT1 haplotype to Japanese methamphetamine use disorder. Int. J. Neuropsychopharmacol. 9 (2006) 77-81
20. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5 (2005) 6-13
21. Johansson I., Lundqvist E., Dahl M.L., and Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6 (1996) 351-355
22. Johansson I., Oscarson M., Yue Q.Y., Bertilsson L., Sjoqvist F., and Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46 (1994) 452-459
23. Jori A., Caccia S., Guiso A., Ballabio M., and Garattini S. Selective storage of p-hydroxy-d-amphetamine in the dopaminergic nerve terminals. Biochem. Pharmacol. 28 (1979) 1205-1207
24. Kendler K.S., Prescott C.A., Myers J., and Neale M.C. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch. Gen. Psychiatry 60 (2003) 929-937
25. Kubota T., Yamaura Y., Ohkawa N., Hara H., and Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol. 50 (2000) 31-34
26. Lin L.Y., Di Stefano E.W., Schmitz D.A., Hsu L., Ellis S.W., Lennard M.S., Tucker G.T., and Cho A.K. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab. Dispos. 25 (1997) 1059-1064
27. Maezawa Y., Yamauchi M., Toda G., Suzuki H., and Sakurai S. Alcohol-metabolizing enzyme polymorphisms and alcoholism in Japan. Alcohol Clin. Exp. Res. 19 (1995) 951-954
28. Malaiyandi V., Sellers E.M., and Tyndale R.F. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin. Pharmacol. Ther. 77 (2005) 145-158
29. Nishida Y., Fukuda T., Yamamoto I., and Azuma J. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 10 (2000) 567-570
30. Nishiyama T., Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Inada T., Furukawa T., and Ozaki N. Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder. Pharmacogenomics J. 5 (2005) 89-95
31. Nomura A., Ujike H., Tanaka Y., Otani K., Morita Y., Kishimoto M., Morio A., Harano M., Inada T., Yamada M., Komiyama T., Sekine Y., Iwata N., Sora I., Iyo M., Ozaki N., and Kuroda S. Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence. Neurosci. Lett. 400 (2006) 158-162
32. Ramamoorthy Y., Tyndale R.F., and Sellers E.M. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11 (2001) 477-487
33. Sato M., Numachi Y., and Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr. Bull. 18 (1992) 115-122
34. Sham P.C., and Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann. Hum. Genet. 59 (1995) 97-105
35. Someya T., Suzuki Y., Shimoda K., Hirokane G., Morita S., Yokono A., Inoue Y., and Takahashi S. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population. Psychiatry Clin. Neurosci. 53 (1999) 593-597
36. Tateishi T., Chida M., Ariyoshi N., Mizorogi Y., Kamataki T., and Kobayashi S. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin. Pharmacol. Ther. 65 (1999) 570-575
37. Taylor W.A., and Sulser F. Effects of amphetamine and its hydroxylated metabolites on central noradrenergic mechanisms. J. Pharmacol. Exp. Ther. 185 (1973) 620-632
38. Tsuang M.T., Bar J.L., Harley R.M., and Lyons M.J. The Harvard Twin Study of Substance Abuse: what we have learned. Harv. Rev. Psychiatry 9 (2001) 267-279
39. Ujike H., Harano M., Inada T., Yamada M., Komiyama T., Sekine Y., Sora I., Iyo M., Katsu T., Nomura A., Nakata K., and Ozaki N. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J. 3 (2003) 242-247
40. Ujike H., and Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann. N. Y. Acad. Sci. 1025 (2004) 279-287
41. Wang S.L., Huang J.D., Lai M.D., Liu B.H., and Lai M.L. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin. Pharmacol. Ther. 53 (1993) 410-418
42. Wang S.L., Lai M.D., and Huang J.D. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab. Dispos. 27 (1999) 385-388
43. Wenger G.R., and Rutledge C.O. A comparison of the effects of amphetamine and its metabolites, p-hydroxyamphetamine and p-hydroxynorephedrine, on uptake, release and catabolism of 3H-norepinephrine in cerebral cortex of rat brain. J. Pharmacol. Exp. Ther. 189 (1974) 725-732